Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for BioCorRx (BICX) over the last 17 years, with Q2 2025 value amounting to -$0.08.

  • BioCorRx's EPS (Basic) rose 3793.74% to -$0.08 in Q2 2025 from the same period last year, while for Jun 2025 it was -$0.08, marking a year-over-year increase of 3793.74%. This contributed to the annual value of -$0.49 for FY2024, which is 808.64% down from last year.
  • Latest data reveals that BioCorRx reported EPS (Basic) of -$0.08 as of Q2 2025, which was up 3793.74% from -$0.06 recorded in Q1 2025.
  • BioCorRx's 5-year EPS (Basic) high stood at -$0.06 for Q1 2025, and its period low was -$0.26 during Q1 2021.
  • In the last 5 years, BioCorRx's EPS (Basic) had a median value of -$0.13 in 2022 and averaged -$0.14.
  • As far as peak fluctuations go, BioCorRx's EPS (Basic) tumbled by 4685.01% in 2021, and later surged by 6006.45% in 2025.
  • Quarter analysis of 5 years shows BioCorRx's EPS (Basic) stood at -$0.2 in 2021, then increased by 17.37% to -$0.16 in 2022, then grew by 28.12% to -$0.12 in 2023, then fell by 1.02% to -$0.12 in 2024, then surged by 30.99% to -$0.08 in 2025.
  • Its EPS (Basic) stands at -$0.08 for Q2 2025, versus -$0.06 for Q1 2025 and -$0.12 for Q4 2024.